

MAR 26 2001



K010089
Real Patient Wireless
Ambulatory EEG
JANUARY 8, 2001

Section E – 510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR § 807.92.

Name: Cameron Mahon
Director of R & D

Address: Excel Tech, Ltd.
2568 Bristol Circle
Oakville, Ontario
Canada, L6H 5S1

Telephone: (905) 829-5300

Fax: (905) 829-5304

E-mail: research@xltek.com

Common Names: Real Patient Wireless Ambulatory EEG

Classification Name: Electroencephalograph

Predicate Devices: Wireless Ambulatory EEG [510(k) #K001103].

Description: The Real Patient Wireless Ambulatory EEG is a self-contained, battery-powered digital electroencephalograph that uses a wireless communication system (cellular telephony or low power short distance protocol). As a stand-alone device, it acquires and stores electrical signals from the brain and transmits them to the Excel NeuroWorks EEG [510(k) # K980214], which displays, stores and archives these signals.

The Real Patient Wireless Ambulatory EEG provides an option for the distribution of EEG data via a wired or wireless communication system using TCP/IP, Intranet, Internet, Cellular Telephony or low power short distance protocol, whereas the Wireless Ambulatory uses a wireless communication system (cellular telephony or low power short distance protocol).

The Wireless Ambulatory EEG consists of the main unit and a battery charging/isolation unit.

It works with any good quality patient leads/electrodes that have safety touch connectors and are legally marketed in accordance with FDA requirements. As a stand-alone unit, the real Patient Wireless Ambulatory EEG utilizes analog amplifiers and A/D converters to store acquired signals from the patient. The battery charging/isolation unit provides power to the Real Patient Wireless Ambulatory EEG and can act as the main isolation barrier between the patient applied parts and the device.

Substantial Equivalence:

As a stand-alone device the Real Patient Wireless Ambulatory EEG is substantially equivalent in terms of safety and effectiveness to the XLTEK Wireless Ambulatory EEG device [510(k) #K001103].

Both devices are used to acquire electrical signals from the brain using the same types of electrodes, however the Real Patient Wireless Ambulatory EEG provides an option for the distribution of EEG data via a wired or wireless communication system using TCP/IP, Intranet, Internet, Cellular Telephony or low power short distance protocol.

Indications for Use:

The Real Patient Wireless Ambulatory EEG is designed to be used in hospital and clinical settings by trained medical personnel.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

MAR 26 2001

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Debbie Davy
Research and Development Administration
Excel Tech, Ltd.
2568 Bristol Circle
Oakville, Ontario
Canada L6H 5S1

Re: K010089
Trade Name: Real Patient Wireless Ambulatory EEG
Regulatory Class: II
Product Code: GWQ
Dated: January 8, 2001
Received: January 11, 2001

Dear Ms. Davy:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Ms. Debbie Davy

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

Miriam C. Probst
for Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Section D – Statement of Indications for Use

Page 1 of 1

510(k) Number (if known): K010089

Device Name: Wireless Ambulatory EEG

Indications for Use: The XLTEK Wireless Ambulatory EEG is a battery-powered digital electroencephalograph that uses a wireless communication system (cellular telephony or low power short distance protocol). As a stand-alone device, it acquires and stores electrical signals from the brain and transmits them to the Excel NeuroWorks EEG [510(k) # K980214], which acquires, displays, stores and archives these signals.

The Wireless Ambulatory EEG is designed to be used in hospital and clinical settings by trained medical personnel.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Miriam C. Provost
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

Prescription Use ☒ 510(k) Number K010089
~~Over The Counter Use~~
(Per 21§ CFR 801.109)

(Optional Format 1-2-96)